The Goldline Pharmaceutical IPO is heading for one of the most heavily subscribed SME issues of the month, with the Rs 11.61 crore offer drawing exceptional retail and HNI demand on its closing day. The Goldline Pharmaceutical IPO has been subscribed 175.87x times overall by midday on May 14. The grey market premium stands at Rs 25, pointing to a listing price of around Rs 68.
The Nagpur-based pharmaceutical marketing company opened the issue on May 12 with a price band of Rs 41-43 per share. Bidding closes today, May 14, allotment is scheduled for May 15, and listing on the BSE SME platform is set for 19 May, 2026.
Subscription split
Retail and HNI investors have driven the bulk of the demand. Retail investors have shown interest with bids for 285.83x the shares available. The Non-Institutional Investor (NII) category has been subscribed 292.88x. Qualified Institutional Buyers (QIBs) have subscribed 11.52x. Data last updated on 14 May, 11:00 AM. QIBs had stayed muted at 1.31 times across the first two days before jumping to 11.52x once Day 3 opened.
Day-wise subscription tells the story of building momentum: Day 1 closed at 20.79x, Day 2 at 93.19x, and Day 3 at 212.45x as of late morning.
For retail applicants, the heavy oversubscription turns allotment into a lottery. Statistically, approximately 1 in 286 applicants will receive allotment. Ahead of the public issue, Goldline had raised Rs 3.15 crore from anchor investors on May 11.
Grey market signals
GMP has steadily climbed through the subscription window. The premium opened at ₹8 on May 8-9, climbed to ₹15 on May 10, ₹17 on May 11, and ₹25 by today. At the current level, the GMP-based listing estimate works out to ₹68 (+58%) over the upper band of Rs 43. The stability of the GMP through a volatile week, including the Sensex correction earlier this week, points to genuine grey market conviction rather than fleeting hype.
The business
Goldline doesn't actually manufacture its medicines. The company mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. Its portfolio covers general medicine, antibiotics, cardiology, diabetology, gynaecology, paediatrics, and wellness categories.
Goldline Pharmaceutical Limited was established in 2005, with operations primarily based in Nagpur and a growing presence across multiple Indian states. Promoters Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal bring decades of pharma industry experience between them.
The numbers
Revenue came in at Rs 28.06 crore for FY25, with PAT margin around 10%. The company has clocked a 19% revenue CAGR over the past two years. At the upper price band, the IPO is valued at 10.48 times FY25 earnings, a clear discount to the 13-15 times P/E range that listed peers in pharma marketing typically command.
Where the money goes
The fresh issue proceeds will primarily go toward debt repayment, with the rest set aside for general corporate purposes. There's no expansion capex baked into the offering, so investors are paying for a deleveraged balance sheet rather than new growth.
For retail investors
SME IPOs come with their own quirks. Lot sizes are large, with a single lot at 3,000 shares and retail required to apply for two lots, meaning a Rs 2.58 lakh minimum ticket. Listing day moves can swing sharply in either direction, and post-listing liquidity is thinner than on mainboard stocks. The asset-light model reduces fixed costs but introduces supply chain and quality risks tied to contract manufacturers, and pending tax proceedings of around Rs 3.34 crore are worth keeping on the radar.
FAQs
What is the Goldline Pharmaceutical IPO subscription status? As of 11:00 AM on May 14, the issue was subscribed 212.45 times. QIB at 11.52x, NII at 292.88x, and Retail at 285.83x.
What is the Goldline Pharmaceutical IPO GMP today? GMP stands at Rs 25, implying an expected listing price of around Rs 68, a 58% premium over the Rs 43 upper band.
When is the allotment and listing? Allotment is scheduled for May 15. Listing on BSE SME is set for May 19.
What is the IPO price band and lot size? Price band is Rs 41 to Rs 43 per share. Lot size is 3,000 shares, with retail investors required to apply for a minimum of two lots, or Rs 2.58 lakh.
What are the chances of retail allotment? With retail subscription at 236.95 times, allotment is by lottery, with roughly 1 in 237 applicants likely to receive shares.
Discussion 0
No comments yet
Be the first to share your thoughts!